Novel Technology for the Detection of Low Abundance Protein

描述(申请人提供)：我们提出了一种检测体液中低丰度蛋白的新技术，并初步应用于精神健康生物标记物。生物标记物发现面临的最大挑战之一是需要分离高丰度和低丰度蛋白质，以便更容易和准确地检测后者。该技术是一种新型的层析平台，利用独特的功能化微结构从临床组织样本中捕获和纯化目标分析物。它不使用传统的珠子、过滤器或磁铁。我们相信，该方法将是样品制备领域的一项潜在突破，并将应用于大量低丰度生物标志物的分析。为了验证所提出的技术，该技术将被应用于神经元生物标志物的检测。在这项SBIR的第一阶段，我们计划从血清中恢复人神经丝蛋白。由于它们在中枢神经系统中的特殊定位，在这个隔室之外的神经丝蛋白的存在可能表明中枢神经系统的损伤和/或疾病。体液中神经丝蛋白的存在可以作为中枢神经系统疾病的敏感指标，包括多发性硬化症、帕金森氏症和艾滋病毒痴呆症。这一第一阶段的SBIR将演示在拟议的层析技术中作为目标分析物的神经细丝的原则证明检测，并设计将在第二阶段建造的自动化仪器。 公共卫生相关性：我们建议开发一种检测体液中低丰度蛋白的新技术，初步应用于一种名为神经丝的精神健康生物标记物。由于它们在中枢神经系统中的特殊定位，在这个隔室之外的神经丝蛋白的存在可能表明中枢神经系统的损伤和/或疾病。体液中神经丝蛋白的存在可以作为中枢神经系统疾病的敏感指标，包括多发性硬化症、帕金森氏症和艾滋病毒痴呆症。

DESCRIPTION (provided by applicant): We propose a novel technology for detection of low abundance protein in body fluids, with initial application to a mental health biomarker. One of the most significant challenges facing biomarker discovery is the need to separate high and low abundance proteins for detection of the latter more easily and with precision. The proposed technology is a novel chromatography platform that utilizes unique functionalized micro-structures to capture and purify target analytes from clinical tissue specimens. It does not utilize conventional beads, filters or magnets. We believe that the proposed method will stand out as is a potential breakthrough in the field of sample preparation and will be applied to analysis of numerous low abundance biomarkers. For validation of the proposed technology, this technology will be applied to the detection of neuronal biomarkers. In Phase I of this SBIR, we plan to recover human neurofilament proteins from serum. Because of their specific localization in the central nervous system, the presence of neurofilament proteins outside of this compartment may indicate damage and/or disease of the central nervous system. The presence of neurofilament proteins in body fluids can serve as a sensitive indicator of central nervous system diseases, including multiple sclerosis, Parkinson's disease and HIV dementia. This Phase I SBIR will demonstrate the proof-of-principle detection of neurofilaments as the target analyte in the proposed chromatography technology and design an automated instrument to be constructed in Phase II. PUBLIC HEALTH RELEVANCE: We propose to develop a novel technology for detection of low abundance protein in body fluids, with initial application to a mental health biomarker called neurofilaments. Because of their specific localization in the central nervous system, the presence of neurofilament proteins outside this compartment may indicate damage and/or disease of the central nervous system. The presence of neurofilament proteins in body fluids can serve as a sensitive indicator of central nervous system diseases, including multiple sclerosis, Parkinson's disease and HIV dementia.